These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38965264)

  • 21. Generation of induced pluripotent stem cells from an individual with early onset and severe hypertrophic cardiomyopathy linked to MYBPC3: c.772G > A mutation.
    Ribeiro M; Jager J; Furtado M; Carvalho T; Cabral JMS; Brito D; Carmo-Fonseca M; Martins S; da Rocha ST
    Hum Cell; 2024 Jul; 37(4):1205-1214. PubMed ID: 38762696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Translational investigation of electrophysiology in hypertrophic cardiomyopathy.
    Flenner F; Jungen C; Küpker N; Ibel A; Kruse M; Koivumäki JT; Rinas A; Zech ATL; Rhoden A; Wijnker PJM; Lemoine MD; Steenpass A; Girdauskas E; Eschenhagen T; Meyer C; van der Velden J; Patten-Hamel M; Christ T; Carrier L
    J Mol Cell Cardiol; 2021 Aug; 157():77-89. PubMed ID: 33957110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypertrophic cardiomyopathy-linked mutation in troponin T causes myofibrillar disarray and pro-arrhythmic action potential changes in human iPSC cardiomyocytes.
    Wang L; Kim K; Parikh S; Cadar AG; Bersell KR; He H; Pinto JR; Kryshtal DO; Knollmann BC
    J Mol Cell Cardiol; 2018 Jan; 114():320-327. PubMed ID: 29217433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severe DCM phenotype of patient harboring RBM20 mutation S635A can be modeled by patient-specific induced pluripotent stem cell-derived cardiomyocytes.
    Streckfuss-Bömeke K; Tiburcy M; Fomin A; Luo X; Li W; Fischer C; Özcelik C; Perrot A; Sossalla S; Haas J; Vidal RO; Rebs S; Khadjeh S; Meder B; Bonn S; Linke WA; Zimmermann WH; Hasenfuss G; Guan K
    J Mol Cell Cardiol; 2017 Dec; 113():9-21. PubMed ID: 28941705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium-glucose cotransporter 2 inhibitors.
    Wijnker PJM; Dinani R; van der Laan NC; Algül S; Knollmann BC; Verkerk AO; Remme CA; Zuurbier CJ; Kuster DWD; van der Velden J
    Cardiovasc Res; 2024 Mar; 120(3):301-317. PubMed ID: 38240646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. iPSC-Based Modeling of Variable Clinical Presentation in Hypertrophic Cardiomyopathy.
    Escribá R; Larrañaga-Moreira JM; Richaud-Patin Y; Pourchet L; Lazis I; Jiménez-Delgado S; Morillas-García A; Ortiz-Genga M; Ochoa JP; Carreras D; Pérez GJ; de la Pompa JL; Brugada R; Monserrat L; Barriales-Villa R; Raya A
    Circ Res; 2023 Jul; 133(2):108-119. PubMed ID: 37317833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MLP-deficient human pluripotent stem cell derived cardiomyocytes develop hypertrophic cardiomyopathy and heart failure phenotypes due to abnormal calcium handling.
    Li X; Lu WJ; Li Y; Wu F; Bai R; Ma S; Dong T; Zhang H; Lee AS; Wang Y; Lan F
    Cell Death Dis; 2019 Aug; 10(8):610. PubMed ID: 31406109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MYBPC3-c.772G>A mutation results in haploinsufficiency and altered myosin cycling kinetics in a patient induced stem cell derived cardiomyocyte model of hypertrophic cardiomyopathy.
    Steczina S; Mohran S; Bailey LRJ; McMillen TS; Kooiker KB; Wood NB; Davis J; Previs MJ; Olivotto I; Pioner JM; Geeves MA; Poggesi C; Regnier M
    J Mol Cell Cardiol; 2024 Jun; 191():27-39. PubMed ID: 38648963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigating
    Shemer Y; Mekies LN; Ben Jehuda R; Baskin P; Shulman R; Eisen B; Regev D; Arbustini E; Gerull B; Gherghiceanu M; Gottlieb E; Arad M; Binah O
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360639
    [No Abstract]   [Full Text] [Related]  

  • 30. Generation of two iPSC lines from hypertrophic cardiomyopathy patients carrying MYBPC3 and PRKAG2 variants.
    Manhas A; Jahng JWS; Vera CD; Shenoy SP; Knowles JW; Wu JC
    Stem Cell Res; 2022 May; 61():102774. PubMed ID: 35413566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Divergent effects of adrenaline in human induced pluripotent stem cell-derived cardiomyocytes obtained from hypertrophic cardiomyopathy.
    Prajapati C; Ojala M; Aalto-Setälä K
    Dis Model Mech; 2018 Feb; 11(2):. PubMed ID: 29361520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics.
    Bhagwan JR; Mosqueira D; Chairez-Cantu K; Mannhardt I; Bodbin SE; Bakar M; Smith JGW; Denning C
    J Mol Cell Cardiol; 2020 Aug; 145():43-53. PubMed ID: 32531470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phenotypic recapitulation and correction of desmoglein-2-deficient cardiomyopathy using human-induced pluripotent stem cell-derived cardiomyocytes.
    Shiba M; Higo S; Kondo T; Li J; Liu L; Ikeda Y; Kohama Y; Kameda S; Tabata T; Inoue H; Nakamura S; Takeda M; Ito E; Takashima S; Miyagawa S; Sawa Y; Hikoso S; Sakata Y
    Hum Mol Genet; 2021 Jul; 30(15):1384-1397. PubMed ID: 33949662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.
    Jaffré F; Miller CL; Schänzer A; Evans T; Roberts AE; Hahn A; Kontaridis MI
    Circulation; 2019 Jul; 140(3):207-224. PubMed ID: 31163979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An integration-free iPSC line ZZUNEUi028-A derived from a patient with hypertrophic cardiomyopathy carrying a heterozygous mutation (c. 1504 C > T) in MYBPC3 gene.
    Cheng D; Zhang S; Li X; Wang L; Dong J; Sang H
    Stem Cell Res; 2022 Aug; 63():102848. PubMed ID: 35772297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Contraction Stress Model of Hypertrophic Cardiomyopathy due to Sarcomere Mutations.
    Cohn R; Thakar K; Lowe A; Ladha FA; Pettinato AM; Romano R; Meredith E; Chen YS; Atamanuk K; Huey BD; Hinson JT
    Stem Cell Reports; 2019 Jan; 12(1):71-83. PubMed ID: 30554920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isogenic Pairs of hiPSC-CMs with Hypertrophic Cardiomyopathy/LVNC-Associated ACTC1 E99K Mutation Unveil Differential Functional Deficits.
    Smith JGW; Owen T; Bhagwan JR; Mosqueira D; Scott E; Mannhardt I; Patel A; Barriales-Villa R; Monserrat L; Hansen A; Eschenhagen T; Harding SE; Marston S; Denning C
    Stem Cell Reports; 2018 Nov; 11(5):1226-1243. PubMed ID: 30392975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Establishment of an induced pluripotent stem cell line (ZJULLi004-A) from a hypertrophic cardiomyopathy patient carrying MYBPC3/c.3764C>A mutation.
    Sun Y; Zhou J; Wang H; Wang H; Chen X; Gong T; Liang P; Jiang C
    Stem Cell Res; 2022 Oct; 64():102898. PubMed ID: 36041398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutations in DNAJC19 cause altered mitochondrial structure and increased mitochondrial respiration in human iPSC-derived cardiomyocytes.
    Janz A; Walz K; Cirnu A; Surjanto J; Urlaub D; Leskien M; Kohlhaas M; Nickel A; Brand T; Nose N; Wörsdörfer P; Wagner N; Higuchi T; Maack C; Dudek J; Lorenz K; Klopocki E; Ergün S; Duff HJ; Gerull B
    Mol Metab; 2024 Jan; 79():101859. PubMed ID: 38142971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells.
    Lan F; Lee AS; Liang P; Sanchez-Freire V; Nguyen PK; Wang L; Han L; Yen M; Wang Y; Sun N; Abilez OJ; Hu S; Ebert AD; Navarrete EG; Simmons CS; Wheeler M; Pruitt B; Lewis R; Yamaguchi Y; Ashley EA; Bers DM; Robbins RC; Longaker MT; Wu JC
    Cell Stem Cell; 2013 Jan; 12(1):101-13. PubMed ID: 23290139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.